We have attempted to make the dengue vaccine more affordable than other innovative vaccines

Gary Dubin, President, Global Vaccine Business Unit, Takeda, and Dion Warren, Head of Multi-Country Organization, India & Southeast Asia, Takeda explain to Viveka Roychowdhury why the manufacturing collaboration with Biological E for the dengue vaccine is a key cornerstone of Takeda’s global commitment to fight dengue as it will help accelerate public health impact not just in India but in other countries as well.

Warren highlights the high sense of urgency regarding dengue in India, with over 2.3 lakh cases in 2022, compared to just over 12,000 cases in 2006.

Dubin also gives more details on Takeda’s long-term Make in India strategy for launching more critical portfolios in the India market.